Fury Gold Mines Limited (TSX and NYSE American: FURY) (“Fury ” or the “Company ”) is pleased to announce that the 2026 drill ...

The state sued Step Up on Second and other organizations in January 2024 alleging fraud related to the Homekey program.

Phased review by EMA aims to accelerate assessment of company's investigational drug daraxonrasib in pancreatic cancer based on unprecedented clinical results from pivotal Phase 3 RASolute 302 trial R ...

The planned Phase 3 trial in approximately 750 postmenopausal women with osteoporosis, with a primary endpoint of total hip bone mineral density ...

Specific Clinical Protocols to Address Unique Physiological Risks in Paediatric & Geriatric Patients, for Safer, More Effective Treatments Presentation Title: Combating Sarcopenic Obesity in ...

(Nasdaq: IONS) and partner AstraZeneca today announced that the CARDIO-TTRansform Phase 3 trial for eplontersen in patients with transthyretin-mediated amyloid cardiomyopathy (ATTR-CM) did not meet ...

Last year, state lawmakers set aside $50 million for research into the psychoactive drug, which can treat opioid withdrawal ...

Recent Clinical Progress, Enrollment Achievements, Expanded Intellectual Property Portfolio and Strengthened Financial Position Support a Potentially Transformative 12-Month Value Creation Opportunity ...

Provaris Energy Ltd (ASX:PV1, OTC:GBBLF, FRA:WS90) has completed a $1 million placement to support key 2026 technical milestones across its compressed hydrogen and liquid CO₂ storage and transport ...

Breakthrough T1D, the leading global type 1 diabetes (T1D) research and advocacy organization and SAB Biotherapeutics, Inc. (Nasdaq: SABS), a clinical-stage biopharmaceutical company developing a ...

CRANBROOK, BC / ACCESS Newswire / July 3, 2026 / Eagle Plains Resources Ltd. (TSXV:EPL)(OTCQB:EGPLF) ("EPL" or "Eagle ...